RiverVest Venture Partners related stories
All articles and analysis
RiverVest appoints CFORiverVest Venture Partners has named Sivan Weitzman as chief financial officer. Previously, she was the CFO at Halman Aldubi Investment House.
- RiverVest closes fourth fund at $184.4 mln
RiverVest Venture Partners, a life sciences venture firm, has closed its oversubscribed fourth fund at $184.4 million. According to the firm, RiverVest has funded 47 and exited or taken public 22 life science companies.
- Mirum Pharmaceuticals nabs $120 mln Series A in NEA-led round
Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has secured $120 million in Series A financing. New Enterprise Associates led the round with participation from Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.
- RiverVest Venture Partners rakes in over $167 mln for fourth fund
RiverVest Venture Partners has raised over $167 million for its fourth fund, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1725443/000172544318000001/xslFormDX01/primary_doc.xml With offices in St. Louis, Cleveland and San Diego, the venture firm invests in life science companies.
- Cardialen takes in $17 mln Series B
Minneapolis-based Cardialen Inc, a medical device company, has raised $17 million in Series B funding. RiverVest Venture Partners led the round with participation from Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital.
- OncoResponse grabs $40 mln Series B
Houston, Texas-based OncoResponse, an immunotherapy company, has closed $40 million in Series B financing. RiverVest Venture Partners led the round.